Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTMX NASDAQ:EDIT NASDAQ:RVMD NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$2.28+8.6%$2.24$0.40▼$3.10$376M2.183.84 million shs4.24 million shsEDITEditas Medicine$2.76+9.5%$2.71$0.91▼$4.12$248.18M2.161.67 million shs1.99 million shsRVMDRevolution Medicines$40.50+4.0%$37.33$29.17▼$62.40$7.57B1.121.95 million shs1.71 million shsSRPTSarepta Therapeutics$18.71+1.4%$17.78$10.41▼$138.81$1.83B0.498.85 million shs5.17 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics+8.57%+11.76%+5.07%-13.64%+82.40%EDITEditas Medicine+9.52%+7.39%+9.09%+44.50%-21.14%RVMDRevolution Medicines+3.98%+6.66%+10.44%-1.44%-4.50%SRPTSarepta Therapeutics+1.35%+2.80%+15.07%-56.50%-86.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTMXCytomX Therapeutics$2.28+8.6%$2.24$0.40▼$3.10$376M2.183.84 million shs4.24 million shsEDITEditas Medicine$2.76+9.5%$2.71$0.91▼$4.12$248.18M2.161.67 million shs1.99 million shsRVMDRevolution Medicines$40.50+4.0%$37.33$29.17▼$62.40$7.57B1.121.95 million shs1.71 million shsSRPTSarepta Therapeutics$18.71+1.4%$17.78$10.41▼$138.81$1.83B0.498.85 million shs5.17 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTMXCytomX Therapeutics+8.57%+11.76%+5.07%-13.64%+82.40%EDITEditas Medicine+9.52%+7.39%+9.09%+44.50%-21.14%RVMDRevolution Medicines+3.98%+6.66%+10.44%-1.44%-4.50%SRPTSarepta Therapeutics+1.35%+2.80%+15.07%-56.50%-86.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTMXCytomX Therapeutics 3.00Buy$5.75152.19% UpsideEDITEditas Medicine 2.23Hold$5.1084.78% UpsideRVMDRevolution Medicines 3.00Buy$72.0077.78% UpsideSRPTSarepta Therapeutics 2.07Hold$43.50132.50% UpsideCurrent Analyst Ratings BreakdownLatest SRPT, CTMX, EDIT, and RVMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/5/2025RVMDRevolution MedicinesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$99.009/3/2025EDITEditas MedicineWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$3.00 ➝ $4.008/25/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell8/20/2025SRPTSarepta TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$17.008/18/2025RVMDRevolution MedicinesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$75.008/18/2025RVMDRevolution MedicinesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$80.008/15/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $5.008/15/2025RVMDRevolution MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$67.008/15/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$12.008/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$4.00 ➝ $6.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTMXCytomX Therapeutics$138.10M2.72$0.36 per share6.30($0.01) per share-228.00EDITEditas Medicine$32.31M7.68N/AN/A$1.63 per share1.69RVMDRevolution Medicines$11.58M653.77N/AN/A$13.47 per share3.01SRPTSarepta Therapeutics$1.90B0.96$2.44 per share7.68$15.99 per share1.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTMXCytomX Therapeutics$31.87M$0.564.07N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)EDITEditas Medicine-$237.09M-$2.85N/AN/AN/A-608.88%-200.25%-68.57%11/3/2025 (Estimated)RVMDRevolution Medicines-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$0.87N/A1.71N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)Latest SRPT, CTMX, EDIT, and RVMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025EDITEditas Medicine-$0.41-$0.63-$0.22-$0.63$1.81 million$3.58 million8/6/2025Q2 2025RVMDRevolution Medicines-$0.94-$1.31-$0.37-$1.31$0.50 millionN/A8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTMXCytomX TherapeuticsN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTMXCytomX TherapeuticsN/A4.204.20EDITEditas MedicineN/A2.772.77RVMDRevolution Medicines0.1311.7911.79SRPTSarepta Therapeutics0.842.891.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTMXCytomX Therapeutics67.77%EDITEditas Medicine71.90%RVMDRevolution Medicines94.34%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipCTMXCytomX Therapeutics6.60%EDITEditas Medicine2.10%RVMDRevolution Medicines8.20%SRPTSarepta Therapeutics7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTMXCytomX Therapeutics170164.91 million154.03 millionOptionableEDITEditas Medicine23089.92 million88.03 millionOptionableRVMDRevolution Medicines250186.93 million171.60 millionOptionableSRPTSarepta Therapeutics1,37297.71 million90.29 millionOptionableSRPT, CTMX, EDIT, and RVMD HeadlinesRecent News About These CompaniesEventide Asset Management LLC Lowers Position in Sarepta Therapeutics, Inc. $SRPTSeptember 6 at 8:44 AM | marketbeat.comSarepta Therapeutics, Inc. $SRPT Stock Holdings Lifted by EcoR1 Capital LLCSeptember 6 at 8:27 AM | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Shares Up 6.1% - Still a Buy?September 5 at 4:16 PM | marketbeat.comSarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic YearSeptember 5 at 10:11 AM | businesswire.comSarepta Therapeutics, Inc. $SRPT Shares Purchased by 683 Capital Management LLCSeptember 4 at 7:42 AM | marketbeat.comADAR1 Capital Management LLC Acquires 82,919 Shares of Sarepta Therapeutics, Inc. $SRPTSeptember 4 at 7:41 AM | marketbeat.comSarepta Therapeutics, Inc. $SRPT Shares Sold by Vestal Point Capital LPSeptember 4 at 7:17 AM | marketbeat.comPDT Partners LLC Raises Stock Holdings in Sarepta Therapeutics, Inc. $SRPTSeptember 4 at 6:26 AM | marketbeat.comSarepta Therapeutics (SRPT) Fell Despite Reporting Good ResultsSeptember 3 at 7:50 AM | finance.yahoo.comSarepta Therapeutics, Inc. $SRPT Shares Sold by Braidwell LPSeptember 3 at 7:42 AM | marketbeat.comSarepta Therapeutics Restructures Amid ELEVIDYS ChallengesSeptember 1, 2025 | tipranks.comTrexquant Investment LP Makes New $12 Million Investment in Sarepta Therapeutics, Inc. $SRPTAugust 31, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Cooper Co (COO) and Amylyx Pharmaceuticals Inc (AMLX)August 30, 2025 | theglobeandmail.comNorthern Trust Corp Reduces Position in Sarepta Therapeutics, Inc. $SRPTAugust 30, 2025 | marketbeat.comSarepta Therapeutics Completes Convertible Notes ExchangeAugust 29, 2025 | tipranks.comSRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class ActionAugust 29, 2025 | globenewswire.comSarepta Therapeutics, Inc. $SRPT Holdings Boosted by Hsbc Holdings PLCAugust 28, 2025 | marketbeat.comRaymond James Financial Inc. Decreases Position in Sarepta Therapeutics, Inc. $SRPTAugust 28, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), Akebia Therapeutics (AKBA) and Sarepta Therapeutics (SRPT)August 27, 2025 | theglobeandmail.comHC Wainwright Reaffirms "Sell" Rating for Sarepta Therapeutics (NASDAQ:SRPT)August 27, 2025 | marketbeat.comSarepta Therapeutics' (SRPT) Sell Rating Reaffirmed at HC WainwrightAugust 27, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Brutal 2025 for Sarepta—Analysts Still Call for 179% UpsideBy Leo Miller | August 12, 2025SRPT, CTMX, EDIT, and RVMD Company DescriptionsCytomX Therapeutics NASDAQ:CTMX$2.28 +0.18 (+8.57%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.30 +0.02 (+0.66%) As of 09/5/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Editas Medicine NASDAQ:EDIT$2.76 +0.24 (+9.52%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.74 -0.01 (-0.54%) As of 09/5/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Revolution Medicines NASDAQ:RVMD$40.50 +1.55 (+3.98%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$40.90 +0.40 (+0.99%) As of 09/5/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Sarepta Therapeutics NASDAQ:SRPT$18.71 +0.25 (+1.35%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$18.63 -0.08 (-0.41%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
